Aardvark Therapeutics, Inc (AARD)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

Aardvark Therapeutics, Inc (AARD) is down 42.1% since the beginning of the year. At $8 per share, AARD is trading 57.6% below its 52-week high of $18.

Aardvark Therapeutics, Inc (AARD) has returned -42.10% so far this year and -37.55% over the past 12 months.

Based on dividend-adjusted daily data since Feb 13, 2025, AARD's average daily return is +0.12%, while the average monthly return is +3.04%. At this rate, an investment would double in approximately 1.9 years.

Historically, 39% of months were positive and 61% were negative. The best month was Sep 2025 with a return of +60.1%, while the worst month was Mar 2026 at -69.8%. The longest winning streak lasted 2 consecutive months, and the longest losing streak was 3 months.

On a daily basis, AARD closed higher 51% of trading days. The best single day was Jul 10, 2026 with a return of +52.0%, while the worst single day was Mar 2, 2026 at -56.2%.

Aardvark Therapeutics, Inc has an annualized alpha of -1.23%, beta of 1.74, and R2 of 0.06 versus S&P 500 Index. Calculated based on daily prices since February 13, 2025.

• This stock participated in 341.98% of S&P 500 Index downside but only 59.93% of its upside - more exposed to losses than it benefited from rallies.
• R2 of 0.06 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

AARD ranks 35 for risk / return — below 35% of stocks on our site. The returns aren't fully compensating for the risk involved. This isn't necessarily a dealbreaker, but factor it into your decision — especially if you're risk-averse.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Aardvark Therapeutics, Inc. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Aardvark Therapeutics, Inc was 80.01%, occurring on Jun 10, 2026. The portfolio has not yet recovered.

The current Aardvark Therapeutics, Inc drawdown is 56.35%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Aardvark Therapeutics, Inc over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Aardvark Therapeutics, Inc is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.